{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:13:10Z","timestamp":1788545590810,"version":"build-2803163510"},"reference-count":52,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Angelini Pharma S.p.A."},{"name":"Fondazione Lottomatica"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Objectives: Major depressive disorder (MDD) frequently co-occurs with substance use disorders, resulting in greater clinical severity and poorer outcomes. Sedative\u2013hypnotic\/anxiolytic agents (SHA) are commonly used to manage anxiety and insomnia, also in MDD. However, their long-term intake might lead to misuse and physical and cognitive complications. Trazodone, an antidepressant with sedative and anxiolytic properties, has been proposed as an option in SHA detoxification, but data on patients with comorbid MDD and SHA use disorders (MDD+SHA-UD) are limited. This study retrospectively evaluated the effects of a three-month treatment with extended-release trazodone in this population. Methods: Seventy-four outpatients with MDD+SHA-UD treated with extended-release trazodone were evaluated at baseline and after one and three months. Depressive symptoms were assessed using the Hamilton Depression Rating Scale. Secondary outcomes included anxiety (Hamilton Anxiety Rating Scale), sleep disturbances (Pittsburgh Sleep Quality Index), physical symptoms (Hamilton Depression\u2013Anxiety subscales, 36-Item Short-Form Health Survey), cognitive functioning (Perceived Deficits Questionnaire\u2013Depression, 5-item), and quality of life (World Health Organization-Five Well-Being Index). Results: Trazodone was associated with a significant reduction in depressive symptoms (p &lt; 0.001), with 47.3% of the initial sample achieving remission at endpoint. Improvements were also observed in measures of anxiety, physical symptoms, subjective sleep quality, perceived cognitive functioning, and quality of life (all p &lt; 0.001). Side effects were mild (25.7% at one month) and declined over time. Conclusions: In this uncontrolled preliminary study, extended-release trazodone was associated with significant improvements across multiple symptom domains in MDD+SHA-UD, warranting controlled investigation.<\/jats:p>","DOI":"10.3390\/jcm15176874","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:25:56Z","timestamp":1788542756000},"page":"6874","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extended-Release Trazodone in Comorbid Major Depressive and Sedative\u2013Hypnotic\/Anxiolytic Use Disorders: A Real-World Preliminary Evaluation of Multidimensional Outcomes"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7457-0426","authenticated-orcid":false,"given":"Marco","family":"Di Nicola","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Department of Neurosciences, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7597-6916","authenticated-orcid":false,"given":"Maria","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9450-8205","authenticated-orcid":false,"given":"Francesca","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6252-2600","authenticated-orcid":false,"given":"Ilaria","family":"Marcelli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bella","sequence":"additional","affiliation":[{"name":"Service of Clinical Psychology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Service of Clinical Psychology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Franza","sequence":"additional","affiliation":[{"name":"Service of Clinical Psychology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-8752","authenticated-orcid":false,"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Department of Neurosciences, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, September 12). Depressive Disorder (Depression). News-Room Fact Sheet, 29 August 2025. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jad.2025.05.018","article-title":"Physical symptoms and inflammatory levels characterize post-COVID-19 depressive episodes compared to non-post-COVID-19 depression","volume":"383","author":"Pepe","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102507","DOI":"10.1016\/j.eclinm.2024.102507","article-title":"Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: An international scoping review","volume":"70","author":"Brandt","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alabaku, O., Yang, A., Tharmarajah, S., Suda, K., Vigod, S., and Tadrous, M. (2023). Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0284389"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20451253221145561","DOI":"10.1177\/20451253221145561","article-title":"Enduring neurological sequelae of benzodiazepine use: An internet survey","volume":"13","author":"Huff","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/bcp.14537","article-title":"Non-medical use of benzodiazepines and GABA analogues in Europe","volume":"87","author":"Hockenhull","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajem.2021.06.022","article-title":"Predictors of clinical severity in subjects attending the emergency department for substance use: A ten-year cross-sectional study","volume":"49","author":"Covino","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12954-025-01153-8","article-title":"A qualitative study of benzodiazepine\/z-drug and opioid co-use patterns and overdose risk","volume":"22","author":"Family","year":"2025","journal-title":"Harm Reduct. J."},{"key":"ref_9","unstructured":"European Union Drugs Agency (2025, August 25). European Drug Report 2025: Trends and Developments. Available online: https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025_en."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/1570159X22666240827165327","article-title":"Major depression in comorbidity with substance use disorders: Patients\u2019 features and clinical-neurobiological rationale of antidepressant treatments","volume":"23","author":"Martinotti","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/ADM.0b013e318277e9e5","article-title":"Dose-related effects for the precipitation of psychopathology by opioid or tranquilizer\/sedative nonmedical prescription use: Results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"7","author":"Schepis","year":"2013","journal-title":"J. Addict. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e6105","DOI":"10.1002\/gps.6105","article-title":"Alcohol and substance use in older adults with treatment-resistant depression","volume":"39","author":"Srifuengfung","year":"2024","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jad.2024.07.142","article-title":"Prevalence and clinical correlates of benzodiazepine use in patients with major depressive disorder","volume":"363","author":"Wang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_15","first-page":"247","article-title":"Personalized treatment of depression based on the patient\u2019s psychopathology: The case for intravenous or intramuscular trazodone in the acute treatment of depression with psychomotor agitation, irritability, or insomnia and the subsequent transition to extended-release trazodone (Contramid\u00ae)","volume":"30","author":"Fagiolini","year":"2025","journal-title":"J. Psychopathol."},{"key":"ref_16","first-page":"137","article-title":"Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: Pharmacology and clinical practice","volume":"54","author":"Cuomo","year":"2019","journal-title":"Riv. Psichiatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12991-025-00563-z","article-title":"Targeting heterogeneous depression with trazodone prolonged release: From neuropharmacology to clinical application","volume":"24","author":"Fagiolini","year":"2025","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e3580","DOI":"10.1002\/brb3.3580","article-title":"Impact of trazodone once-a-day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study","volume":"14","author":"Tellone","year":"2024","journal-title":"Brain Behav."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2174\/1570159X21666230403080624","article-title":"Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: The role of extended-release trazodone","volume":"21","author":"Pepe","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_20","first-page":"1","article-title":"Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal symptoms and taper outcome","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s10072-021-05845-4","article-title":"Brand new norms for a good old test: Northern Italy normative study of Mini Mental State Examination","volume":"43","author":"Foderaro","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_22","unstructured":"Ashton, C.H. (2002). Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual), Institute of Neuroscience, Newcastle University. [Revised ed.]. Available online: https:\/\/www.benzo.org.uk\/manual\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/0269881118788826","article-title":"Efficacy of vortioxetine on the physical symptoms of major depressive disorder","volume":"32","author":"Christensen","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0895-4356(98)00094-8","article-title":"The Italian SF-36 Health Survey: Translation, validation and norming","volume":"51","author":"Apolone","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0895-4356(98)00108-5","article-title":"The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: Results from the IQOLA Project","volume":"51","author":"Ware","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"ref_26","unstructured":"Ware, J., Kosinski, M., and Keller, S.D. (1994). SF-36 Physical and Mental Health Summary Scales: A User\u2019s Manual, Health Assessment Lab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: A systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"ref_28","unstructured":"US Food and Drug Administration (2026, August 17). Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Available online: https:\/\/www.fda.gov\/media\/116737\/download."},{"key":"ref_29","unstructured":"International Council for Harmonisation (2005). ICH Harmonised Tripartite Guideline E14: The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, ICH. Available online: https:\/\/www.ema.europa.eu\/en\/ich-e14-clinical-evaluation-qt-qtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-scientific-guideline."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Siwek, M., Chrobak, A.A., Krupa, A.J., Gorostowicz, A., Juryk, A., and Dudek, D. (2025). Trazodone effectiveness in depression: Impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1525498"},{"key":"ref_31","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2025, August 25). Rapporto OsMed Sull\u2019uso dei Farmaci in Italia, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/2769025\/2025.04.03_Pierluigi-Russo_Rapporto-OsMed_Roma.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","article-title":"Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001\u20132014","volume":"74","author":"Bushnell","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"McHugh, R.K., Votaw, V.R., Trapani, E.W., and McCarthy, M.D. (2023). Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1129447"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Greenwald, M.K., Moses, T.E.H., Lundahl, L.H., and Roehrs, T.A. (2023). Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1103739"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ajad.13639","article-title":"Age and gender differences in motives for z-drug misuse: Findings from the 2015 to 2019 NSDUH survey","volume":"33","author":"Ellis","year":"2024","journal-title":"Am. J. Addict."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/add.14596","article-title":"Treatment-resistant depression as risk factor for substance use disorders: A nationwide register-based cohort study","volume":"114","author":"Brenner","year":"2019","journal-title":"Addiction"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.2174\/0929867328666211115124149","article-title":"GABA system in depression: Impact on pathophysiology and psychopharmacology","volume":"29","author":"Arone","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100270","DOI":"10.1016\/j.dadr.2024.100270","article-title":"Benzodiazepine use for anxiety disorders is associated with increased long-term risk of mood and substance use disorders: A large-scale retrospective cohort study","volume":"12","author":"Sun","year":"2024","journal-title":"Drug Alcohol. Depend. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, Y.-C., Lin, H.-T., Lu, M.-L., Huang, M.-C., Chen, C.-H., Wu, T.-H., Wang, S., Mao, W.-C., Kuo, P.-H., and Chen, H.-C. (2019). The association between the sedative loads and clinical severity indicators in the first-onset major depressive disorder. Front. Psychiatry, 10.","DOI":"10.3389\/fpsyt.2019.00129"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2045125317753340","article-title":"Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation","volume":"8","author":"Fluyau","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/NDT.S399948","article-title":"Long-term treatment with trazodone once-a-day (TzOAD) in patients with MDD: An observational, prospective study","volume":"19","author":"Shrashimirova","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1007\/s11606-025-09499-2","article-title":"Joint clinical practice guideline on benzodiazepine tapering: Considerations when risks outweigh benefits","volume":"40","author":"Brunner","year":"2025","journal-title":"J. Gen. Intern. Med."},{"key":"ref_43","unstructured":"US Food and Drug Administration (2025, July 29). FDA Drug Safety Communication: FDA Requiring Boxed Warning Updated to Improve Safe Use of Benzodiazepine Drug Class, Available online: https:\/\/www.fda.gov\/media\/142368\/download."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Calandre, E.P., Morillas-Arques, P., Molina-Barea, R., Rodriguez-Lopez, C.M., and Rico-Villademoros, F. (2011). Trazodone plus pregabalin combination in the treatment of fibromyalgia: A two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet. Disord., 12.","DOI":"10.1186\/1471-2474-12-95"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40122-024-00624-3","article-title":"Efficacy and safety of trazodone and gabapentin fixed-dose combination in patients affected by painful diabetic neuropathy: Randomized, controlled, dose-finding study","volume":"13","author":"Tesfaye","year":"2024","journal-title":"Pain Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev-clinpsy-050718-095557","article-title":"Estrogen, Stress, and Depression: Cognitive and Biological Interactions","volume":"15","author":"Albert","year":"2019","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14737175.2025.2470973","article-title":"Emerging strategies and clinical recommendations for the management of novel depression subtypes","volume":"25","author":"Chiappini","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00406-023-01617-7","article-title":"Physical and cognitive correlates, inflammatory levels, and treatment response in post-COVID-19 first-onset vs. recurrent depressive episodes","volume":"274","author":"Pepe","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0887-6177(03)00096-9","article-title":"Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: A meta-analysis","volume":"19","author":"Barker","year":"2004","journal-title":"Arch. Clin. Neuropsychol."},{"key":"ref_50","first-page":"20","article-title":"Extended-release trazodone in major depressive disorder: A randomized, double-blind, placebo-controlled study","volume":"6","author":"Sheehan","year":"2009","journal-title":"Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","article-title":"A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder","volume":"35","author":"Fagiolini","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_52","unstructured":"Agenzia Italiana del Farmaco (2026, August 17). Riassunto delle Caratteristiche del Prodotto, Available online: https:\/\/api.aifa.gov.it\/aifa-bdf-eif-be\/1.0.0\/organizzazione\/219\/farmaci\/22323\/stampati?ts=RCP."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6874\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:39:28Z","timestamp":1788543568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":52,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176874"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176874","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}